Xinxiang Tuoxin Pharmaceutical Co.Ltd. - Asset Resilience Ratio
Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) has an Asset Resilience Ratio of 7.00% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s Asset Resilience Ratio has changed over time. See Xinxiang Tuoxin Pharmaceutical Co.Ltd. financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 301089 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥115.56 Million | 7.0% |
| Total Liquid Assets | CN¥115.56 Million | 7.00% |
Asset Resilience Insights
- Limited Liquidity: Xinxiang Tuoxin Pharmaceutical Co.Ltd. maintains only 7.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Xinxiang Tuoxin Pharmaceutical Co.Ltd. Industry Peers by Asset Resilience Ratio
Compare Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621 |
Drug Manufacturers - Specialty & Generic | 2.04% |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
|
Jw Pharmac
KO:001060 |
Drug Manufacturers - Specialty & Generic | 3.65% |
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Samjin Pharm
KO:005500 |
Drug Manufacturers - Specialty & Generic | 0.25% |
Annual Asset Resilience Ratio for Xinxiang Tuoxin Pharmaceutical Co.Ltd. (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Xinxiang Tuoxin Pharmaceutical Co.Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.31% | CN¥105.15 Million ≈ $15.39 Million |
CN¥1.67 Billion ≈ $243.69 Million |
-7.95pp |
| 2024-12-31 | 14.27% | CN¥250.88 Million ≈ $36.71 Million |
CN¥1.76 Billion ≈ $257.29 Million |
+3.90pp |
| 2023-12-31 | 10.37% | CN¥190.70 Million ≈ $27.91 Million |
CN¥1.84 Billion ≈ $269.10 Million |
-2.66pp |
| 2022-12-31 | 13.03% | CN¥240.16 Million ≈ $35.14 Million |
CN¥1.84 Billion ≈ $269.73 Million |
-2.80pp |
| 2021-12-31 | 15.83% | CN¥220.62 Million ≈ $32.28 Million |
CN¥1.39 Billion ≈ $203.94 Million |
-- |
About Xinxiang Tuoxin Pharmaceutical Co.Ltd.
Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates in China. It offers nucleoside (acid) products, such as pyrimidine series, purine series, and nucleotide series; nucleoside series, including citicoline sodium, ribavirin, inosine, acyclovir, cytosine, 5-fluorocytosine, cytidine, uridine; an… Read more